Lower urinary tract symptoms and benign prostatic hyperplasia

Minerva Urologica e Nefrologica

Volumn 56, Issue 2, 2004, Pages 109-122

  Skolarikos, A ^a   Thorpe, A C ^b   Neal, D E ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b FREEMAN HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Bladder neck obstruction; Prostatic hyperplasia, diagnosis; Prostatic hyperplasia, physiopathology; Prostatic hyperplasia, therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PHENOXYBENZAMINE; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT;

BLADDER OBSTRUCTION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DROWSINESS; DRUG EFFECT; DRUG MECHANISM; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GYNECOMASTIA; HEADACHE; HUMAN; KIDNEY FAILURE; LOWER URINARY TRACT SYMPTOM; MEDICAL CARE; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PHYTOTHERAPY; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; RECORDING; REVIEW; SIDE EFFECT; SMOOTH MUSCLE; SYMPTOM; SYNCOPE; URETHRA DISEASE; URINARY TRACT HEMORRHAGE; URINARY TRACT INFECTION; URINE RETENTION;

ACUTE DISEASE; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUALITY OF LIFE; URINARY BLADDER NECK OBSTRUCTION; URINARY RETENTION;

EID: 3843060049     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. De la Rosette JJ. What we do and don't know about benign prostatic hyperplasia. Curr Opin Urol 2000;10:1-2.
2. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA et al. Treatment for benign prostatic hyperplasia among community dwelling men. The Olmsted county study of urinary tract symptoms and health status. J Urol 1999;162:1301-6.
3. Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor β gene polymorphism at codon 10. Carcinogenesis 2003;6:343.
4. Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003;57:57-65.
5. Walsh PC. Human benign prostatic hyperplasia: etiological considerations. Prog Clin Biol Res 1984;145:1-25.
6. Byrne RL, Leung H, Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 1996;77:627-33.
7. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Can Res 2002;8:2541-52.
8. DiSanto ME, Stein R, Chang S, Hypolite JA, Zheng Y, Zderic S et al. Alteration in expression f myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Am J Physiol Cell Physiol 2003;285:C1397-410.
9. Sarma AV, Wei JT, Jacobson DJ, Dunn RL, Roberts RO, Girman CJ et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health study. Urology 2003;61:108-91.
10. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am 1990;17:495-507.
11. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 1997;157:1711-7.
12. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs R, Fourcade R et al. The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int 2003;92:575-80.
13. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
14. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care 1995;33:AS145-55.
15. Lytton B, Emery JM, Harvard BM. The incidence of benign prostatic obstruction. J Urol 1968;99:639-45.
16. Walsh A. Indications for prostatic surgery and selection of operation. In: Fitzpatrick JM, Krane RJ, editors. The Prostate. London: Churchill Livingstone; 1989.p.137-42.
17. Steyn M. Just old age? A study of prostatism in general practice. Fam Pract 1988;5:193-5.
18. Smith RA, Wake R, Soloway MS. Benign prostatic hyperplasia. Postgrad Med 1988;83:79-85.
19. Thorpe AC, Cleary R, Coles J, Vernon S, Reynolds J, Neal DE. Deaths and complications following prostatectomy in 1400 men in the northern region of England. Br J Urol 1994;74:559-65.
20. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardization of terminology of lower urinary tract function. Report from the standardization sub committee of the international continence society. Neurourol Urodyn 2002;21:167-78.
21. Van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S et al. The standardization of terminology in Nocturia. Report from the standardization sub committee of the international continence society. Neurourol Urodyn 2002;21:179-83.
22. nd, Jones K, Williford WO, Kutner MH, Issa MN, Lepor H. Changes in nocturia from medical treatment of prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003;170:145-8.
23. Matthiesen T, Ritting S, Norgaard JP, Pedersen EB, Djurhuus JC. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996;156:1292-9.
24. Homma Y, Yamaguchi T, Kondo Y, Horie S, Takahashi S, Kitamura T. Significance of nocturia in the international prostate symptom score for benign prostatic hyperplasia. J Urol 2002;167:172-6.
25. Styles RA, Ramsden PD, Neal DE. The outcome of prostatectomy on chronic retention of urine. J Urol 1991;146:1029-33.
26. Djavan B, Nickel JC, de la Rosette J, Abrams P. The urologist view of BPH progression: results of an international survey. Eur Urol 2002;41:490-6.
27. Rhodes T, Blue Bell PA, Jacobson D, Jacobsen SJ, Rochester MN. Longitudinal prostate volume in a community based sample: long-term follow-up in the Olmsted County study of urinary symptoms and health status among men. J Urol 2002;167:269.
28. Djavan B, Wammack R, Dobrovits M, Fariborz B, Kramer G, Hruby S et al. Predictors of progression in men with mild symptoms of bladder outlet obstruction. J Urol 2002;167:268.
29. McConnell JD. The long-term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol 2002;167:264.
30. Speakman M. Tamsulosin reduces the risk of acute urinary retention. J Urol 2002;167:375.
31. Neal DE. Watchful waiting or drug therapy for benign prostatic hyperplasia? Lancet 1997;350:305-6.
32. Tubaro A, Trucchi A, Miano L. Investigation of benign prostatic hyperplasia. Curr Opin Urol 2003;13:17-22.
33. Boyarsky S, Jones G, Paulson D, Prout G. A new look at bladder neck obstruction by the food and drug administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1977;68:29-32.
34. Madsen P, Iversen P. A point system for selecting operative candidates. In: Hinman F Jr, editor. Benign Prostatic Hypertrophy. New York: Springer-Verlag; 1983.p.763-5.
35. Mebust W, Roizo R, Schroeder F, Villers A. Correlations between pathology clinical symptoms and the course of the disease. In: Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S et al., editors. Proceedings of the International Consultation on benign prostatic hyperplasia. Geneva: WHO; 1991.p.51-62.
36. Donovan JL, Abrams P, Peters TJ, Kay HE, Reynard J, Chapple C et al. The ICS-BPH Study: the psychometric validity and reliability of the ICS male questionnaire. Br J Urol 1996;77:554-62.
37. Braun MH, Sommer F, Haupt G, Mathers MJ, Reiferath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur Urol 2003;44:588-94.
38. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. The international prostate symptom score in a community sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995;75:622-30.
39. Thorpe AC, Cleary R, Coles J, Neal DE. Nottingham health profile measurement in the assessment of clinical outcome after prostatectomy. Br J Urol 1995;76:446-50.
40. The EuroQol Group: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
41. Arai Y, Aoki Y, Okubo K, Maeda H, Terada N, Matsuta Y et al. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study. J Urol 2000;164:1206-11.
42. Schultz MW, Chen J, Woo HH, Keech M, Watson ME, Davey PJ. A comparison of techniques for eliciting patient preference in patients with benign prostatic hyperplasia. J Urol 2002;168:155-9.
43. De la Rosette JJ, Witjes WP, Schafer W, Abrams P, Donovan JL, Peters TJ et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the "ICS-BPH" study. Neurourol Urodyn 1998;17:99-108.
44. th International Consultation on Benign Prostatic Hyperplasia. June 25-28, 2000, Paris. Plymouth, UK: Health Publication Ltd; 2001.p.519-33.
45. Griffiths D, Hofner K, Van Maastrigt R, Rollema HJ, Spangberg A, Gleason D. Standardisation of terminology of lower urinary tract function: pressure flow studies of voiding, urethral resistance, and urethral obstruction. Neurourol Urodyn 1997;16:1-18.
46. Neal DE, Ramsden PD, Sharples L, Smith A, Powell PH, Styles RA et al. Outcome of elective prostatectomy. BMJ 1989;299:762-7.
47. Di Silverio F, Sciarra A, D'Eramo G, Casale P, Loreto A, Seccareccia F. Relationship among age, prostate specific antigen and prostate volume in men with lower urinary tract symptoms and in different age groups of men with and without benign and malignant prostatic diseases. Prostate 1998;36:1-7.
48. Wright EJ, Fang J, Metter EJ, Partin AW, Landis P, Chan DW et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002;167:2484-8.
49. Selley S, Donovan JL, Faulkener A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997;1:1-96.
50. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia. A Department of Veterans Affairs cooperative study. J Urol 1998;160:12-6.
51. Donovan JL, Peters TJ, Neal DE, Brookes ST, Gujral S, Chacko KN et al. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement. The CLasP study. J Urol 2000;164:65-70.
52. AUA practice guidelines Committee AUA guideline of management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and tratment recommendations. J Urol 2003;170:530-47.
53. Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology 2001;57:1082-5.
54. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 2002;12:15-8.
55. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002,(1):CD001044.
56. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000,(3):CD001423.
57. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC et al. Comparison of a phytotherapeutic agent (Permixon) with an α-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002;41:497-506, discussion 506-7.
58. Talpur N, Echard B, Bagchi D, Preuss HG. Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats. Mol Cell Biochem 2003;250:21-6.
59. Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998;81:29-33.
60. Kirby RS, Coppinger SW, Corcoran MO, Chapple CR, Flannigan M, Milroy EJ. Prazosin in the treatment of prostatic obstruction: a placebo controlled study. Br J Urol 1987;60:136-42.
61. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003;169:1520-5.
62. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R et al. The α 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned α 1C subtype. Mol Pharmacol 1994;45:703-8.
63. Chapple CR. α adrenoceptor antagonists in the year 2000: is there anything new? Curr Opin Urol 2001;11:9-16.
64. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170(2 Pt 1):498-502.
65. Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003;91:41-4.
66. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo controlled studies. BJU Int 2003;92:257-61.
67. McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained release alfusosin and trial without catheter after acute urinary retention: a prospective, placebo controlled trial. BJU Int 1999;84:622-7.
68. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37:367-80.
69. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 2003;61:354-8.
70. Roehrborn CG, Bruskewitz R, Nickel GC, Glickman S, Cox C, Anderson R et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS study group. Eur Urol 2000;37:528-36.
71. Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L et al. PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:579-84.
72. Clark R, Hermann D, Gabriel H, Wilson T, Morril B, Hobbs S. Effective suppression of dihydrotestosterone (DHT) by GI 198745, a novel, dual 5-α reductase inhibitor. J Urol 1999;161:1037.
73. Roehrborn CG, Boyle PJ, Nickel C, Hoefner K, Andriole G. On behalf of the ARIA3001, ARIA3002 and ARIA3003 study investigators. Efficacy and safety of a dual inhibitor or 5-α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
74. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8.
75. O'Leary MP, Roehrborn C, Andriole GL, Nickel C, Boyle P, Hoefner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 2003;92:262-5.
76. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G et al. The efficacy of terazocin, finasteride or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996;335:533-9.
77. Loran O, Pushkar D, Kosko J. Combination of proscar and terazocin in BPH patients with severe obstructive symptoms and large prostate volume. J Urol 2000;163:218.
78. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC et al. Sustained release alfusosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN study group. Eur Urol 1998;34:169-75.
79. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Gary MM et al. Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in the treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-26.
80. Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC. Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001;58:203-9.
81. Freyer P. One thousand cases of total enucleation of the prostate for radical cure of enlargement of that organ. BMJ 1912;2:868.
82. Fuller E. Six successful cases of prostatectomy. J Cutan Genitourin Dis 1985;13:229.
83. Millin T. Retropubic Urinary Surgery. London: Livingstone; 1947.
84. Walsh TN, Kelly DG. Historical review of prostatectomy. In: Fitzpatrick JM, Krane RJ, editors. The Prostate. London: Churchill Livingstone; 1989.p.143-7.
85. Blandy JP. Transurethral prostatectomy. In: Blandy JP, Lytton B, editors. The Prostate. London: Butterworth; 1986.p.51-61.
86. Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF et al. Mortality and reoperation after open and transurethral resection of the prostate. New Engl J Med 1989;320:1120-4.
87. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002;324:1059-61.
88. Emberton M, Neal DE, Black N, Fordham M, Harrison M, McBrien MP et al. Effect of prostatectomy on symptom scoring and quality of life. Br J Urol 1996;77:233-47.
89. Kabelin JN, Gillings PJ, Fraundorfer MR. Holmium:yttrium-aluminium-garnet laser prostatectomy. Mayo Clin Proc 1998;73:792-7.
90. Aho TF, Gilling PJ. Laser therapy for benign prostatic hyperplasia: a review of recent developments. Curr Opin Urol 2003;13:39-44.
91. Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1 year follow-up. J Urol 1999;162:1640-4.
92. Keoghane SR, Lawrence KC, Gray AM, Doll HA, Hancock AM, Turner K et al. A double blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow up. BJU Int 2000;85:74-8.
93. Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraudorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). J Urol 2003;170(4 pt 1):1270-4.
94. Seki N, Mochida O, Kinukawa N, Sagiyama K, Naito S. Holmium laser enucleation for prostatic adenoma: analysis of learning curve over the course of 70 consecutive cases. J Urol 2003;170:1847-50.
95. De Wildt MJ, Hubregtse M, Ogden C, Carter SS, Debruyne FM, de la Rosette JJ. A 12-month study of the placebo effect in TUMT. Br J Urol 1996;77:221-7.
96. De la Rosette JJ, D'Ancona FC, Debruyne FMJ. Current status of thermotherapy of the prostate. J Urol 1997;157:430-8.
97. Devonec M, Houdelette, Columbeau P, Menguy P, Peneau M. A multicentre study of SHAM versus thermotherapy in benign prostatic hypertrophy. J Urol 1994;151:415.
98. D'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ. High energy thermotherapy (TUMT) versus transurethral resection (TURP) in the treatment of benign prostatic hyperplasia (BPH): results of a prospective randomized study with a 1-year follow-up. J Urol 1997;158:120-5.
99. Thalmann GN, Mattei A, Treuthardt C, Burkhard FC, Studer UE. Transurethral microwave therapy in 200 patients with minimum follow-up of 2 years: urodynamic and clinical results. J Urol 2002;167:2496-501.
100. De la Rosette JJ, Floratos DL, Severens JL, Kiemeney LA, Debruyne FM, Laguna M. Transurethral resection vs microwave thermotherapy of the prostate: a cost consequences analysis. BJU Int 2003;92:713-8.
101. Ramon J, Lynch TH, Eardley I, Ekman P, Frick J, Jungwirth A et al. Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study. Br J Urol 1997;80:128-35.
102. Roehrborn CG, Issa MM, Bruskewitz RC, Naslund MJ, Oesterling JE, Perez-Marrero R et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter US study. Urology 1998;51:415-21.
103. Hill B, Belville W, Bruskewitz R, Issa MM, Perez-Marrero R, Roehrborn C et al. Five-year results of a prospective randomized trial comparing transurethral needle ablation (TUNA) to TURP for treatment of symptomatic BPH. J Urol 2002;167:294.
104. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centres. Eur Urol 2003;44:89-93.
105. Mulligan ED, Lynch TH, Mulvin D, Greene D, Smith JM, Fitzpatrick JM. High intensity focused ultrasound in the treatment of benign prostatic hyperplasia. Br J Urol 1997;79:177-80.
106. Madersbacher S, Klingler CH, Schatzl G, Schmidbauer CP, Marberger M. The urodynamic impact of transrectal high intensity focused ultrasound on bladder outflow obstruction. Eur Urol 1996;30:437-45.
107. Schatzl G, Mardersbacher S, Dyavan B, Lang T, Marberger M. Two year results of transurethral resection of the prostate versus four "less invasive" treatment options. Eur Urol 2000;37:695-701.
108. Desautel MG, Burney TL, Diaz PA, Austria A, Badlani GH. Outcome of Vaportrode transurethral vaporization of the prostate using pressure flow urodynamic criteria. Urology 1998;51:1013-7.
109. Hammadech MY, Madaan S, Hines J, Philp T. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 2003;61:1166-71.
110. Neal DE, Neal RR, Donovan J. Benign Prostatic Hyperplasia. A systematic Review. Chapter in Health Care Needs Assessment. 1999. Full chapter on the web: http://hcna.radcliffe-online.com/urinframe.html
111. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2002;361:1359-67.